Healthcare

Clarity Pharmaceuticals jumped about 13 per cent (at the time of writing on 31 July 2026), sharply outperforming both the broader market and a healthcare sector that was under pressure as heavyweight CSL slid. The move made Clarity one of the strongest performers on …

Argent BioPharma is a clinical- and commercial-stage biopharmaceutical company that rebranded from MGC Pharmaceuticals in March 2026, keeping its RGT listing. It works across cannabinoid and botanical therapeutics, with European manufacturing sites in Slovenia and Malta, and a pipeline led by an epilepsy candidate, …

The S&P/ASX 200 Health Care index fell as its largest constituent, CSL, dropped almost 5 per cent (at the time of writing on 31 July 2026), unwinding much of the gain it had booked mid-week. The weakness was broad across the sector: Cochlear lost …

Imugene (ASX:IMU) has streamlined its development strategy around its lead CAR-T therapy, azer-cel, while reporting encouraging early clinical progress and additional regulatory support during 2026. As a clinical-stage biotechnology company, future milestones will depend on continued clinical development alongside maintaining sufficient funding for its …

Racura Oncology (ASX:RAU) has entered a new stage of clinical development after dosing the first patient in its Phase 1 HARNESS-1 study during June 2026. Following its rebrand from Race Oncology, the company is advancing its lead therapy, RC220, while expanding clinical trial sites …

The Melbourne lung-imaging company has spent the past year collecting regulatory clearances and reimbursement approvals across three continents. Yet its recent share-price volatility highlights that for 4DMedical, the real test is turning approvals into paying scan volumes.

Ryman Healthcare Ltd (ASX:RYM) traded at $1.98, up 4.21%, as at the time of writing on 31 July 2026. The broader S&P/ASX 200 (ASX:XJO) was trading at 8,984.80 points, gaining 0.19%, while the S&P/ASX 200 Health Care Index (ASX:XHJ) declined 2.24% to 26,526.60 points.